A three-year UT Dallas study tracking nearly 4,000 adults to age 94 says brain function can climb at any age. The biology is plausible. The catch is that the people measuring the gain are the same people patenting the yardstick.
Autoimmune & InflammationA new Nature Immunology study identifies an alveolar lung-like cell hiding inside the thymus, where it appears to teach the immune system not to attack your real lungs.
Autoimmune & InflammationA 28-patient feasibility trial put severe gum-disease patients on three cycles of a 750-calorie ProLon diet. Inflammation markers trended lower; clinical gum measures weren't reported. The biology question is real; the data is thin.
Drugs & FDAThe Trump administration on Thursday proposed closing the product-hopping loophole that lets drugmakers reset Medicare's negotiation clock by tweaking inactive ingredients. It is the same fix the same administration quietly tabled in October.
Brain & AgingA new Cell paper finds Alzheimer's brains are riddled with the same mutations that drive blood cancers, in the immune cells that are supposed to be protecting neurons.
Nutrition & FoodA Frontiers in Public Health survey of 8,336 Brazilians over 60 found older men reach for the saltshaker most. Buried in the same paper: the shaker only accounts for 6 to 20 percent of total sodium. The other 70-plus percent already arrived from the factory.
Nutrition & FoodKennedy got eight organizations across U.S. medical training and 73 medical schools to commit to nutrition in licensing, accreditation, and a 40-hour pledge. The board exam matters; the rest is partly hedging.
Brain & AgingAn OIST team caught the mouse brain firing acetylcholine the moment an expected reward failed to land. That surge is what lets the animal switch strategy. Close to half of community-dwelling older adults are on drugs that block the same receptors.
Drugs & FDAA new chemical UV filter Europe approved in 1999 just cleared the FDA after a 21-year wait, while Americans relied on ingredients the agency's own 2019 review could not call safe.
Brain & Aging54,804 Danes followed for a quarter-century: less dementia from vegetable nitrate, more from drinking water. The risk signal shows up at roughly one-ninth of what the US EPA still permits.
Autoimmune & InflammationA Brazilian team gave EPA-heavy fish oil to a non-obese diabetic rat strain for eight weeks. Glucose, insulin sensitivity, and lipids all moved in the friendlier direction. The T-cell balance shifted alongside them, and that is the part of the paper worth chewing on.
Brain & AgingAn ETH Zurich team spent nearly twenty years tracing why Alzheimer's nerve cells run out of energy, and the answer points to a protein the amyloid-clearing drugs never touched.
InvestigationsA federally funded field trial used a controlled fire whirl to burn up to 95% of a crude oil pool while cutting soot by 40%, raising the question of why the standard in-situ burn, with its measured worker-lung cost, has gone unchallenged for thirty-five years.
Nutrition & FoodResearchers at Guangdong Pharmaceutical University argue Polygonum multiflorum could become the next pattern-baldness lead. The follicle biology is interesting. The case series of acute liver failure on four continents are not.
Metabolic & WeightLilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.
Metabolic & WeightEli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe
Autoimmune & InflammationA Shanghai lab reports a steroid from a Yunnan mountain plant, already sold over the counter to bodybuilders, suppresses the same kidney-fibrosis pathway Big Pharma keeps circling and never quite closes on.
InvestigationsA polished hernia FAQ walks patients through recovery time, return-to-work, and lifestyle. It skips the question with 26,153 pending lawsuits behind it, and the no-mesh option the international guideline still keeps on the table.
Metabolic & WeightStructure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.
InvestigationsPolice escorted ADA members out of New Orleans on Friday for passing out an editorial against Trump's NIH overhaul. The shove was bad. The editorial defending the status quo has a credibility problem the press is mostly missing.
Metabolic & WeightA VA cohort of 606,000 diabetic veterans on GLP-1 drugs showed lower risks of new substance use disorders and large drops in overdose and drug-related death versus a peer diabetes drug. The mechanism story is where it gets interesting.
Brain & AgingHarvard used MERFISH to image roughly 1,100 odorant receptors across the mouse nose at once and found tidy stripes, not chaos. The clinical stakes for smell loss just got harder to wave off.
Drugs & FDAFDA flags Abiomed's 14Fr Low Profile Introducer Kit after a higher than expected complaint rate of clots forming on the device during prolonged Impella CP support. Three serious injuries reported, no deaths. The pattern keeps growing.
InvestigationsFor one strange year, the EWG hiking-boots crowd and the MAHA red-hat moms were fighting the same pesticide war. Then Trump invoked the Defense Production Act on behalf of Bayer, the final MAHA report quietly stopped mentioning glyphosate, and a coalition that was actually winning got stomped by a C
Drugs & FDAThe FDA approved Coloplast's Titan Prime inflatable penile prosthesis on June 3, 2026. For the men whose vasculature is past saving, it is a meaningful device upgrade. For most men with new ED, the more useful conversation is what the small arteries are failing to do years before the coronaries noti
Drugs & FDAFDA's new gene therapy draft guidance invites sponsors to lean on "platform knowledge" to streamline submissions, six months after the agency revoked Sarepta's AAVrh74 platform designation following three patient deaths.